Increasing the Efficacy of Stem Cell Therapy <i>via</i> Triple-Function Inorganic Nanoparticles

Chen, Fang; Zhao, Eric; Hableel, Ghanim; Hu, Tao; Kim, Taeho; Li, Jingting; Gonzalez‐Pech, Natalia I.; Cheng, D.K.W.; Lemaster, Jeanne E.; Xie, Yijun; Grassian, Vicki H.; Sen, George L.; Jokerst, Jesse V.

doi:10.1021/acsnano.9b00653

Cited by 46 publications

(35 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many challenges need to be overcome, significant progress has been made in recent years based on various materials, e . g ., black phosphorus, mesoporous silica, metal-organic framework (MOF) 168 , carbon nanomaterials 169 , magnetic nanomaterials 170 , as well as their combinations 171 .…”

Section: Inorganic Materials For Drug Deliverymentioning

confidence: 99%

Recent progress in drug delivery

Wang

et al. 2019

Acta Pharmaceutica Sinica B

568

272

View full text Add to dashboard Cite

Drug delivery systems (DDS) are defined as methods by which drugs are delivered to desired tissues, organs, cells and subcellular organs for drug release and absorption through a variety of drug carriers. Its usual purpose to improve the pharmacological activities of therapeutic drugs and to overcome problems such as limited solubility, drug aggregation, low bioavailability, poor biodistribution, lack of selectivity, or to reduce the side effects of therapeutic drugs. During 2015–2018, significant progress in the research on drug delivery systems has been achieved along with advances in related fields, such as pharmaceutical sciences, material sciences and biomedical sciences. This review provides a concise overview of current progress in this research area through its focus on the delivery strategies, construction techniques and specific examples. It is a valuable reference for pharmaceutical scientists who want to learn more about the design of drug delivery systems.

show abstract

Section: Inorganic Materials For Drug Deliverymentioning

confidence: 99%

Recent progress in drug delivery

Wang

et al. 2019

Acta Pharmaceutica Sinica B

568

272

View full text Add to dashboard Cite

show abstract

“…Therefore, it is urgent to understand the molecular mechanism of MIRI and develop appropriate interventions or treatment strategies. Previous studies have confirmed that nanoparticles are helpful to promote myocardial tissue repair, 37,38 so nanoparticle therapy in MIRI has captured more and more attention.…”

Section: Discussionmentioning

confidence: 99%

Effect of Quercetin-Loaded Mesoporous Silica Nanoparticles on Myocardial Ischemia-Reperfusion Injury in Rats and Its Mechanism

Liu¹,

Li²,

Hu³

et al. 2021

IJN

View full text Add to dashboard Cite

Background Quercetin has potential value in treating cardiovascular diseases, but it is not suitable for clinical application due to its own water solubility. The limitation of quercetin can be distinctly ameliorated by delivering it with nanocarriers. Objective To determine the effect of quercetin-loaded mesoporous silica nanoparticles (Q-MSNs) on myocardial ischemia-reperfusion injury in rats and its mechanism. Methods Q-MSNs were synthesized, and the morphology of Q-MSNs and MSNs was characterized by transmission electron microscopy and dynamic light scattering technique, respectively. Healthy rats were enrolled and randomly divided into a sham operation control group, an ischemia-reperfusion (IR) group, an IR+Q group, an IR+Q-MSNs group, and an MSNs group (each n = 10). Rats in the sham operation group were not treated with ischemia reperfusion, but given normal perfusion meantime. Rats in the sham operation control group, IR group, and MSNs group were given normal saline for 10 days before ischemia reperfusion, and rats in the IR+Q group and IR+Q-MSNs group were given drugs by gavage for 10 days before ischemia reperfusion. Primary myocardial cells were sampled from SD neonatal rats to construct hypoxia/reoxygenation myocardial cell models. The myocardial cells were assigned to a control group, IR group, quercetin (Q) group, Q-MSNs group, and MSNs group. Except for the control group, all the other groups were treated with hypoxia/reoxygenation. Cells in the Q group were treated with quercetin (10 μM, 20 μM, 40 μM) for 24 h in advance and then treated with measures to cause hypoxia-reoxygenation injury. Cells in the Q-MSNs group were treated with the same concentration of loaded quercetin and the same method used for the Q group. The myocardial apoptosis, myocardial infarction, ventricular remodeling, hemodynamic indexes, physiological and biochemical indexes, and JAK2/STAT3 pathway expression of each group were detected, and the apoptosis, viability, oxidative stress, and JAK2/STAT3 pathway expression of primary myocardial cells in each group were also detected. Results Quercetin significantly activated the JAK2/STAT3 pathway in vivo and in vitro, and MSNs intensified the activation. Compared with quercetin, Q-MSNs were more effective in inhibiting cell apoptosis and oxidative stress, reducing myocardial infarction size, improving ventricular remodeling and cardiac function-related biochemical indexes, and promoting the recovery of cardiac blood flow. Conclusion Q-MSNs can significantly enhance the activation effect of quercetin on JAK2/STAT3 pathway, thus enhancing its protection on the heart of MIRI rats.

show abstract

“…Because of the biological properties of metallic NPs, they have been used for treating myocardial I/R injury, AMI, and heart failure ( Miragoli et al, 2018 ; Chang et al, 2019 ; Chen et al, 2019 ; Lee et al, 2020 ). With biocompatibility and low toxicity, iron oxide NPs are the most common metal NM used in the study of ASCVD.…”

Section: Nanomedicines For Drug Deliverymentioning

confidence: 99%

Advances in Nanomaterials for Injured Heart Repair

Guo

Yang

Wang

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes of mortality worldwide. Because of the limited regenerative capacity of adult myocardium to compensate for the loss of heart tissue after ischemic infarction, scientists have been exploring the possible mechanisms involved in the pathological process of ASCVD and searching for alternative means to regenerate infarcted cardiac tissue. Although numerous studies have pursued innovative solutions for reversing the pathological process of ASCVD and improving the effectiveness of delivering therapeutics, the translation of those advances into downstream clinical applications remains unsatisfactory because of poor safety and low efficacy. Recently, nanomaterials (NMs) have emerged as a promising new strategy to strengthen both the efficacy and safety of ASCVD therapy. Thus, a comprehensive review of NMs used in ASCVD treatment will be useful. This paper presents an overview of the pathophysiological mechanisms of ASCVD and the multifunctional mechanisms of NM-based therapy, including antioxidative, anti-inflammation and antiapoptosis mechanisms. The technological improvements of NM delivery are summarized and the clinical transformations concerning the use of NMs to treat ASCVD are examined. Finally, this paper discusses the challenges and future perspectives of NMs in cardiac regeneration to provide insightful information for health professionals on the latest advancements in nanotechnologies for ASCVD treatment.

show abstract

Increasing the Efficacy of Stem Cell Therapy via Triple-Function Inorganic Nanoparticles

Cited by 46 publications

References 49 publications

Recent progress in drug delivery

Recent progress in drug delivery

Effect of Quercetin-Loaded Mesoporous Silica Nanoparticles on Myocardial Ischemia-Reperfusion Injury in Rats and Its Mechanism

Advances in Nanomaterials for Injured Heart Repair

Contact Info

Product

Resources

About